e-learning
resources
Amsterdam 2015
Sunday, 27.09.2015
Advances in the therapy of lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Enhanced FGFR signaling correlates with erlotinib/bevacizumab response in advanced non-squamous non-small cell lung cancer
Anca Franzini (St Gallen, Switzerland), Anca Franzini, Florent Baty, Martin Brutsche
Source:
International Congress 2015 – Advances in the therapy of lung cancer
Session:
Advances in the therapy of lung cancer
Session type:
Oral Presentation
Number:
266
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Anca Franzini (St Gallen, Switzerland), Anca Franzini, Florent Baty, Martin Brutsche. Enhanced FGFR signaling correlates with erlotinib/bevacizumab response in advanced non-squamous non-small cell lung cancer. Eur Respir J 2015; 46: Suppl. 59, 266
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Progression after osimertinib in EGFR T790M-mutated non-small cell cancer patients
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020
Global screening of AKT/PI3K signaling molecules for non-small cell lung cancer and its prognosis
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
Gene modules in non-small cell lung cancer
Source: Annual Congress 2009 - Basic science and lung cancer
Year: 2009
The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer
Source: Eur Respir Rev 2010 19: 186-196
Year: 2010
Targeted therapy in non-small cell lung cancer
Source: Breathe 2012; 8: 206-215
Year: 2012
Hypoxia-response gene signatures as predictive and prognostic biomarkers in advanced non-squamous non-small cell lung cancer patients
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015
Role of chemokines in resectable non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019
Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011
Efficacy of local therapy for oligoprogressive disease after PD-1 blockade in advanced non-small cell lung cancer
Source: Virtual Congress 2021 – COVID-19 and management of lung cancer
Year: 2021
Correlation between the activation of coagulation-fibrinolysis system and prognosis of nonsmall cell lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 231s
Year: 2001
Biological therapies in nonsmall cell lung cancer
Source: Eur Respir J , 49 (3) 1601520; DOI: 10.1183/13993003.01520-2016
Year: 2017
Clinical characterization of non-small cell lung cancer tumors showing neuroendocrine differentiation
Source: Eur Respir J 2002; 20: Suppl. 38, 270s
Year: 2002
Clinical significance and functional roles of FoxM1 in non-small cell lung cancer
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
Soluble non-invasive markers in non-small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 459s
Year: 2005
Radio(chemo)therapy in locally advanced nonsmall cell lung cancer
Source: Eur Respir Rev 2015; 25: 65-70
Year: 2016
A novel biologic classification of non-small cell lung cancer
Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology
Year: 2005
CDCA promotes non-small-cell lung cancer (NSCLC) migration by regulating Akt/Erk1/2 signaling pathways
Source: International Congress 2019 – Thoracic oncology: Treatment, diagnostic options and biology
Year: 2019
Evaluate soluble PD-L1 in plasma in advanced stage non-small cell lung cancer patients
Source: Virtual Congress 2020 – Biological mechanisms of lung cancer
Year: 2020
Anticancer treatment for advanced non-small cell lung cancer
Source: Breathe 2011; 8: 124-133
Year: 2011
Proliferative activity of non-small cell lung cancer after induction chemotherapy
Source: Eur Respir J 2005; 26: Suppl. 49, 328s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept